Scope Fluidics SA

Scope Fluidics operates with a current ratio of 13.06, indicating strong liquidity position relative to short-term obligations. The company's debt-to-equity ratio of 0.01 suggests minimal leverage, with long-term debt amounting to 2,149,000 PLN against total equity of 162,431,000 PLN. However, negative operating cash flow of -46,113,000 PLN and free cash flow of -57,618,000 PLN highlight significant cash outflows. The company's profitability metrics are negative, with return on equity at -28.54% and return on assets at -23.66%. These figures fall below typical industry benchmarks for biotechnology firms, which often prioritize R&D over immediate profitability. Operating income of -47,282,000 PLN and net income of -46,364,000 PLN reflect substantial losses. Scope Fluidics' revenue is concentrated in its core diagnostic and med-tech solutions, with no disclosed geographic diversification in the financial snapshot. The company's business model appears to focus on product development rather than geographic expansion, with no material revenue segments reported. The company's growth trajectory is uncertain, with no revenue history provided and no outlook data available for current or next fiscal year. The negative operating cash flow and free cash flow suggest ongoing capital requirements that could impact future growth. Risk assessment indicates medium liquidity risk due to negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no near-term pressure indicated. The company's capital structure shows minimal debt exposure, but its negative cash flows could necessitate future financing. Recent events include the development of the PCR ONE and BacterOMIC systems, which are central to the company's diagnostic offerings. No recent filings or transcripts were provided in the input data.